Disease · HP_0003394
Muscle spasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Muscle spasm. Diseases, record HP_0003394. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003394
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Muscle spasm
- Open Targets ID
- HP_0003394
- Other names
- Muscle cramps, Muscle spasms
- Highest stage of its drugs
- Approval, for 15 of its 24 drugs, from DailyMed and TTD
Source Open Targets
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | CHEMBL1200636 | Small molecule | Approval | DailyMed | 5 | 2 | 2 | Drugs and targets |
| TOLPERISONE | CHEMBL1076211 | Small molecule | Approval | TTD | 3 | 2 | 2 | Drugs and targets |
| CARISOPRODOL | CHEMBL1233 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CAPSAICIN | CHEMBL294199 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CINOLAZEPAM | CHEMBL2104926 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| CISATRACURIUM | CHEMBL1201248 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| CODEINE PHOSPHATE | CHEMBL6067642 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| DECAMETHONIUM | CHEMBL1190 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets32
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CHRNA1 | Muscle-type nicotinic acetylcholine receptor | 4 | Muscle-type nicotinic acetylcholine receptor antagonist; Muscle-type nicotinic acetylcholine receptor partial agonist | Approval | https://conductscience.org/library/genes/1134 | Drugs and targets |
| CHRNB1 | Muscle-type nicotinic acetylcholine receptor | 4 | Muscle-type nicotinic acetylcholine receptor antagonist; Muscle-type nicotinic acetylcholine receptor partial agonist | Approval | https://conductscience.org/library/genes/1140 | Drugs and targets |
| CHRND | Muscle-type nicotinic acetylcholine receptor | 4 | Muscle-type nicotinic acetylcholine receptor antagonist; Muscle-type nicotinic acetylcholine receptor partial agonist | Approval | https://conductscience.org/library/genes/1144 | Drugs and targets |
| CHRNE | Muscle-type nicotinic acetylcholine receptor | 4 | Muscle-type nicotinic acetylcholine receptor antagonist; Muscle-type nicotinic acetylcholine receptor partial agonist | Approval | https://conductscience.org/library/genes/1145 | Drugs and targets |
| CHRNG | Muscle-type nicotinic acetylcholine receptor | 4 | Muscle-type nicotinic acetylcholine receptor antagonist; Muscle-type nicotinic acetylcholine receptor partial agonist | Approval | https://conductscience.org/library/genes/1146 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| GABBR1 | GABA-B receptor | 1 | GABA-B receptor agonist | Early phase 1 | https://conductscience.org/library/genes/2550 | Drugs and targets |
1 to 10 of 32
See all 32 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00671502 | A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back | Phase 3 | 840 | 2011-11-09 | Lower Back Pain | CARISOPRODOL | Its record names the disease | ClinicalTrials.gov |
| NCT03802565 | Tolperisone in Acute Muscle Spasm of the Back | Phase 2 | 415 | 2020-11-10 | Back Pain, Acute Pain, Back Spasm Upper Back, Back Strain, Muscle Cramp, Muscle Spasm, Low Back Pain | TOLPERISONE | Its record names the disease | ClinicalTrials.gov |
| NCT02814565 | Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin | Phase 3 | 180 | 2019-04-08 | Neck Pain, Back Pain, Spasm | CYCLOBENZAPRINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00715429 | Vitamin D for Painful Nocturnal Leg Cramps | Not applicable | 29 | 2019-09-17 | Leg Cramps, Nocturnal | ERGOCALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04671082 | Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm | Phase 3 | 1,004 | Back Muscle Spasm, Back Pain, Back Strain, Back Spasm Upper, Muscle Spasm, Acute Pain | TOLPERISONE | Its record names the disease | ClinicalTrials.gov | |
| NCT05547750 | Effect of Vitamin K2 in the Treatment of Nocturnal Leg Cramps in Older Population | Not applicable | 200 | Nocturnal Leg Cramps | MENAQUINONE 6 | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06863662 | Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm | Phase 3 | 136 | Acute Low-back Pain, Muscle Spasm; Back Pain | ETORICOXIB, TIZANIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04550793 | Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients | 100 | Stroke, Spasticity, Muscle, Botulism, Ultrasound, Activity of Daily Living | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov | ||
| NCT06274021 | Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury | Early phase 1 | 16 | Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic | BACLOFEN, TIZANIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05683574 | Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil | Phase 3 | 0 | Third Molar Extraction | CYCLOBENZAPRINE HYDROCHLORIDE, ETORICOXIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cyclobenzaprine HCl 15 mg vs Placebo: deaths from any cause | 0 of 90 | 0 of 90 | 180 | NCT02814565 | Trial comparisons |
| Cyclobenzaprine HCl 15 mg vs Placebo: serious adverse events | 0 of 90 | 0 of 90 | 180 | NCT02814565 | Trial comparisons |
| Vitamin D 50,000 U/d x 10d, + Vitamin D 50,000 U Weekly 7 Wks vs Placebo x 10d, + Placebo Weekly 7 Wks: serious adverse events | 0 of 7 | 0 of 6 | 13 | NCT00715429 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0003394
GET https://conductscience.org/api/diseases/v1/HP_0003394/drugs?page=2